Eisai Co., Ltd. (ESALF) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Tokyo, Japan. Le PDG actuel est Haruo Naito.
ESALF a date d'introduction en bourse 2011-04-07, 11,067 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $8.46B.
Eisai Co., Ltd. is a Tokyo-based pharmaceutical company founded in 1941 that develops and markets a diverse portfolio of prescription and over-the-counter products across multiple therapeutic areas. The company's key branded medications include Aricept for Alzheimer's disease and Lewy body dementia, Fycompa for epilepsy, Dayvigo for insomnia, and Lenvima for various cancers including thyroid, renal cell, and hepatocellular carcinoma. Eisai also markets Halaven for breast cancer and liposarcoma, Lyrica for pain management, Pariet for gastrointestinal disorders, and Humira for autoimmune diseases, alongside consumer health products such as vitamin supplements and designated quasi-drugs. The company serves the Japanese market as a leading player in both prescription pharmaceuticals and consumer health categories.
